36.46

1.88% 0.6567

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $36.46, with a volume of 2.84M. It is up +1.88% in the last 24 hours and down -2.95% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$35.80

Open:

$35.77

24h Volume:

2.84M

Relative Volume:

0.80

Market Cap:

$15.76B

Revenue:

$2.31B

Net Income/Loss:

$1.66B

P/E Ratio:

15.85

EPS:

2.3

Net Cash Flow:

$827.02M

1W Performance:

+0.83%

1M Performance:

-2.95%

6M Performance:

+10.49%

1Y Performance:

+29.75%

1-Day Range:

$35.77

$36.52

1-Week Range:

$34.08

$37.28

52-Week Range:

$24.05

$38.00

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1154)

Industry

Biotechnology (648)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	36.45	15.48B	2.31B	1.66B	827.02M	2.30
VRTX Vertex Pharmaceuticals Inc	395.94	101.34B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	481.62	59.64B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	558.01	59.19B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	766.33	47.00B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	350.00	38.12B	3.81B	-644.79M	-669.77M	-6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

01:22 AM

Royalty Pharma’s $2 Billion Debt Raise Could Be a Game Changer for RPRX - simplywall.st

01:22 AM

10:02 AM

Baird Financial Group Inc. Has $1.59 Million Position in Royalty Pharma PLC $RPRX - MarketBeat

10:02 AM

04:49 AM

Amundi Sells 1,316,620 Shares of Royalty Pharma PLC $RPRX - MarketBeat

04:49 AM

04:43 AM

Cutter Capital Management LP Sells 407,965 Shares of Royalty Pharma PLC $RPRX - MarketBeat

04:43 AM

Sep 08, 2025

Panagora Asset Management Inc. Has $1.54 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat

Sep 08, 2025

Is Royalty Pharma plc likely to announce a buyback2025 Price Targets & AI Enhanced Trade Execution Alerts - 뉴스영

Sep 08, 2025

Punch & Associates Investment Management Inc. Boosts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat

Sep 08, 2025